Elizabeth Douville
Founder & Partner @ Amorchem
Montréal, Canada
Elizabeth Douville is a Series A investor at Amorchem in Montréal focused on Biotechnology and Health Care. Dr. Douville joined GeneChem in 1997 as a Manager of the Technologies Fund and was promoted to Vice President in 2001 with the raising of their Therapeutics Fund. In 2006, Dr. Douville became General Partner with the raising of their third fund, AgeChem. As of January 2011, Dr. Douville is co-managing the fourth and latest venture fund, AmorChem.Dr. Douville is an active board member of Alethia Biotherapeutics and she was an active member of the boards of directors of Cytochroma Inc., Ambit Biosciences Inc., LymphoSign Inc. and Chronogen Inc. and was also a board member of Idun Pharmaceuticals Inc. before its sale to Pfizer in 2005. Elizabeth obtained her Ph.D. in biochemistry at the University of Ottawa (1994), studying the role of protein tyrosine kinases in oncogenesis. She then received postdoctoral training at the Imperial Cancer Research Fund in London (U.K.) from 1994 to 1997 where she studied oncogenes and their signal transduction pathways. In 2008, Elizabeth obtained a business certificate degree as part of the “Programme de perfectionnement des cadres supérieurs” (an Executive management and training program) offered by CIREM in collaboration with HEC/University of Montreal.
- Total investments:
- 5
- Last investment:
- Lead investor:
- 60%
Last updated:
For AI agents: llms.txt
Industries Elizabeth Douville invests in
Stages Elizabeth Douville invests in
Countries Elizabeth Douville invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 3 (60%)
- Health Care 2 (40%)
- Therapeutics 2 (40%)
- Medical 1 (20%)
- Diabetes 1 (20%)
Stage
- Series A 2 (40%)
- Series B 1 (20%)
- Series C 1 (20%)
- Funding Round 1 (20%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Located in Montreal, Inversago Pharma is a privately owned Canadian biotech company at clinical-stage, specialized in the development of new therapies focusing on CB1 blockade, based on first-in-class, peripherally-acting, CB1 inverse agonists. The Company aims to provide new treatment options that improve the lives of patients affected bymetabolic conditions such as Diabetic Kidney Disease (DKD), including Diabetic Nephropathy (DN), Type 1 and Type 2 Diabetes (T1D / T2D) Non-Alcoholic Steatohepatitis (NASH), complications of obesity and hypertriglyceridemia (HTG), as well as fibrotic indications such as Progressive Fibrosis – Interstitial Lung Disease (PF-ILD), including Idiopathic Pulmonary Fibrosis (IPF) and other conditions. | $69.3M / Series C / Oct 17, 2022 | ||
| Located in Montreal, Inversago Pharma is a privately owned Canadian biotech company at clinical-stage, specialized in the development of new therapies focusing on CB1 blockade, based on first-in-class, peripherally-acting, CB1 inverse agonists. The Company aims to provide new treatment options that improve the lives of patients affected bymetabolic conditions such as Diabetic Kidney Disease (DKD), including Diabetic Nephropathy (DN), Type 1 and Type 2 Diabetes (T1D / T2D) Non-Alcoholic Steatohepatitis (NASH), complications of obesity and hypertriglyceridemia (HTG), as well as fibrotic indications such as Progressive Fibrosis – Interstitial Lung Disease (PF-ILD), including Idiopathic Pulmonary Fibrosis (IPF) and other conditions. | $35M / Series B / Sep 08, 2020 | ||
| Located in Montreal, Inversago Pharma is a privately owned Canadian biotech company at clinical-stage, specialized in the development of new therapies focusing on CB1 blockade, based on first-in-class, peripherally-acting, CB1 inverse agonists. The Company aims to provide new treatment options that improve the lives of patients affected bymetabolic conditions such as Diabetic Kidney Disease (DKD), including Diabetic Nephropathy (DN), Type 1 and Type 2 Diabetes (T1D / T2D) Non-Alcoholic Steatohepatitis (NASH), complications of obesity and hypertriglyceridemia (HTG), as well as fibrotic indications such as Progressive Fibrosis – Interstitial Lung Disease (PF-ILD), including Idiopathic Pulmonary Fibrosis (IPF) and other conditions. | $7M / Series A / Jul 25, 2018 | ||
| SemaThera is a spin-off company from AmorChem Venture Fund 1, focusing on SEMA 3A protein inhibitor in the treatment of ocular diseases, such as diabetic macular edema. This technology emerges from the laboratory of Dr Mike Sapieha, Hôpital Maisonneuve-Rosement (Montreal, Canada). | $2.6M / Mar 26, 2018 | ||
| Alethia BioTherapeutics, Inc., a biotechnology company, engages in the discovery and development of monoclonal antibody-based therapeutics focusing on the cancer-associated epithelial-to-mesenchymal transition, ovarian cancer, and on cancer-induced bone loss. Its products include Isogranulatimide, a G2 checkpoint inhibitor, which potentiates theresponse to several DNA-damaging chemotherapeutic agents; sCLU, a heterodimeric disulphide-linked glycoprotein of 449 amino acids, the over-expression of which is observed in various malignancies, including prostate, bladder, kidney, breast, colon, and lung tumors; AB-0447, an antigen that is expressed at the surface of ovarian cancer epithelial cells in greater than eighty five percent of malignant tumors; and AB-0440, a cell-surface protease-like protein, whose expression is stimulated early in osteoclast differentiation in response to RANK ligand. The company was founded in 2002 and is based in Montreal, Canada. | $9.2M / Series A / Sep 07, 2010 |
Co-Investors
About Amorchem
AmorChem l.p., our fourth focused fund, was launched in 2011 to increase the commercial potential of the quality academic research carried out in Quebec. AmorChem is focused on investing in promising life science projects originating from Québec-based universities and research centres. AmorChem’s innovative business model involves financingresearch-stage projects to enable them to reach pre-clinical proof-of-concept in a semi-virtual mode. AmorChem will generate returns through a two-pronged exit strategy:
Amorchem Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Elizabeth Douville
Founder & Partner
|
|||
Kevin McBride
Partner and CSO
|
|||
Maxime Pesant
CFO & Partner
|
|||
Maxime Ranger
General Partner
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Elizabeth Douville invest in?
Elizabeth Douville invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series A and Series B stage. Most of the 5 investments tracked by Shizune back companies in Canada. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Elizabeth Douville?
Public channels for Elizabeth Douville include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Elizabeth Douville last invest?
The most recent investment recorded for Elizabeth Douville closed in Oct 2022. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
